The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of overall survival (OS) in patients (pts) with metastatic breast cancer (MBC) according to phosphathidylinositol-3-kinase (PI3K) pathway status.
L. De Mattos-Arruda
No relevant relationships to disclose
M. Oliveira
No relevant relationships to disclose
G. Sánchez-Ollé
No relevant relationships to disclose
D. Moreno-Fernandez
No relevant relationships to disclose
B. Graña
No relevant relationships to disclose
J. Cortes
Consultant or Advisory Role - Eisai; Roche
Honoraria - Roche
M. Bellet
No relevant relationships to disclose
S. Di Cosimo
No relevant relationships to disclose
P. Gomez Pardo
No relevant relationships to disclose
J. Rodon Ahnert
No relevant relationships to disclose
J. M. Perez-Garcia
No relevant relationships to disclose
M. Vidal
No relevant relationships to disclose
E. Muñoz-Couselo
No relevant relationships to disclose
J. Hernandez-Losa
No relevant relationships to disclose
A. Vivancos
Research Funding - Novartis
L. Prudkin
No relevant relationships to disclose
C. Aura
No relevant relationships to disclose
J. Baselga
No relevant relationships to disclose
J. Tabernero
No relevant relationships to disclose
C. Saura
No relevant relationships to disclose